• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer
【24h】

Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer

机译：贝伐单抗治疗方案可降低转移性结肠癌患者的平均血小板量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The risk of thromboemboli is increased in patients with cancer, and this is precipitated by the chemotherapeutic agents. Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody and has an importance in the treatment of metastatic colon cancer. The association between bevacizumab, which is demonstrated to increase the risk of thromboemboli, and mean platelet volume (MPV), which is a marker of thrombocyte function, has been investigated within study. A total of 74 patients with metastatic colon cancer were included in the study and the levels of platelets (PLTs), MPV, and platecrit (PCT) values were recorded in SPSS 16.0 program both at baseline and at the third month. There were significant decreases in 3 parameters (PLT, MPV, and PCT) during the treatment period with bevacizumab (P = .009, P = .001, and P = .000, respectively). Unlike cases with thrombosis, there is a significant decrease in MPV in combination treatments with bevacizumab.
机译：癌症患者中血栓栓塞的风险增加，这是由化学治疗剂引起的。贝伐单抗是一种抗血管内皮生长因子单克隆抗体，在转移性结肠癌的治疗中具有重要意义。已在研究中研究了贝伐单抗和血栓形成平均标志物血小板平均体积（MPV）之间的相关性，贝伐单抗被证明增加了血栓栓塞的风险。这项研究共纳入74名转移性结肠癌患者，并且在基线和第三个月的SPSS 16.0程序中记录了血小板（PLTs），MPV和血小板压积（PCT）值。贝伐单抗治疗期间3个参数（PLT，MPV和PCT）显着降低（分别为P = .009，P = .001和P = .000）。与血栓形成病例不同，贝伐单抗联合治疗的MPV显着降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号